白介素-33在妇科肿瘤中的研究进展

Research progress of IL-33 in gynecological tumors

白介素-33(interleukin-33,IL-33)最初被描述为高内皮静脉中的核蛋白,稳定表达于人及小鼠组织中各种细胞类型的细胞核中,包括内皮细胞、上皮细胞及成纤维细胞样细胞等。IL-33是白介素-1(interleukin-1,IL-1)细胞因子家族的成员,可同时作为转录因子和细胞因子发挥作用。IL-33通过与其特异性受体肿瘤发生抑制蛋白2(suppression of tumorigenicity 2,ST2)和核心受体IL-1受体协同蛋白(IL 1 receptor accessory protein,IL 1RAcP)结合,形成IL-33/ST2信号通路,在免疫介导的疾病如感染、过敏和自身免疫性疾病中发挥着多种重要的作用。近年来,一些研究表明IL-33在调节抗肿瘤免疫和肿瘤生长方面具有潜在的作用,但其确切功能以及其在肿瘤发展中的潜在机制尚不清楚。卵巢癌、宫颈癌和子宫内膜癌是常见的妇科恶性肿瘤,尽管近年来在妇科肿瘤的外科手术切除和全身化疗方面取得了进展,但恶性肿瘤的预后仍然较差。为了进一步个性化治疗,还需要找到其他预测临床病程预后的标志物和可能的治疗靶点。研究恶性肿瘤侵袭性生长和转移相关的分子机制,可能为妇科恶性肿瘤的治疗提供新思路。本文主要综述IL-33的生物学功能及其在妇科肿瘤中的研究进展。

Interleukin-33(IL-33) was originally described as a high-endothelial intravenous nucleoprotein that was steadily expressed in the nuclei of various cell types in human and mouse tissues, including endothelial cells, epithelial cells and fibroblast-like cells. IL-33 forms IL-33/ST2 signaling pathway by binding to suppression of tumorigenicity2(ST2) and IL-1 receptor accessory protein(IL-1 RAcP), and plays a variety of important roles in immune-mediated diseases such as infection, allergy and autoimmune diseases.In recent years, some studies have shown the potential role of IL-33 in regulating anti-tumor immunity and tumor growth, but its exact function and its potential mechanism in tumor development are still unclear. Ovarian, cervical and endometrial cancers are common gynecologic malignancies. Despite recent advances in surgical resection and systemic chemotherapy of gynecologic tumors, the prognosis of malignant tumors is still poor. In order to further individualize treatment, other prognostic markers and potential therapeutic targets for clinical course prediction are needed. The research on the molecular mechanism of invasive growth and metastasis of malignant tumors may provide new ideas for the treatment of gynecological malignant tumors. This article mainly reviews the biological functions of il-33 and its research progress in gynecological tumors.